scispace - formally typeset
L

Liam R. Brunham

Researcher at University of British Columbia

Publications -  126
Citations -  6411

Liam R. Brunham is an academic researcher from University of British Columbia. The author has contributed to research in topics: Familial hypercholesterolemia & Medicine. The author has an hindex of 36, co-authored 107 publications receiving 4999 citations. Previous affiliations of Liam R. Brunham include St. Paul's Hospital & National University of Singapore.

Papers
More filters
Journal ArticleDOI

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.

TL;DR: A critical role is established for intestinal ABCA1 in plasma HDL biogenesis in vivo and the data suggest that HDL derived from intestinalABCA1 is secreted directly into the circulation and that HDL in lymph is predominantly derived from the plasma compartment.
Journal ArticleDOI

Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I

TL;DR: It is concluded that in chow-fed mice, the liver is the single most important source of plasma HDL, and hepatic, but not extrahepatic, Abca1 is critical in maintaining the circulation of mature HDL particles by direct lipidation of hepatic lipid-poor apoA-I, slowing its catabolism by the kidney and prolonging its plasma residence time.
Journal ArticleDOI

Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment.

TL;DR: A new role for Abca1 is established in β-cell cholesterol homeostasis and insulin secretion, and it is suggested that cholesterol accumulation may contribute to β- cell dysfunction in type 2 diabetes.
Journal ArticleDOI

Efflux and atherosclerosis - the clinical and biochemical impact of variations in the abca1 gene

TL;DR: How genetic variation at the ABCA1 locus affects its role in the maintenance of lipid homeostasis and the natural progression of atherosclerosis is reviewed.
Journal ArticleDOI

Regulated cell death pathways in doxorubicin-induced cardiotoxicity

TL;DR: Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.